circVec

About Circio

Circio's mission is to establish its circVec platform as a new gold-standard for nucleic acid and viral therapeutics by leveraging the inherent stability of circular RNA to drive enhanced and durable protein expression. The company has generated compelling preclinical data showing up to 15-fold enhanced and 70-fold more durable expression versus linear mRNA, and is actively pursuing partnerships and internal development across gene therapy, cell therapy, and vaccines. Its strategy involves advancing the circVec platform through its Swedish R&D subsidiary while out-licensing its clinical-stage oncology asset TG01 to external collaborators for further development.

About Circio

Circio's mission is to establish its circVec platform as a new gold-standard for nucleic acid and viral therapeutics by leveraging the inherent stability of circular RNA to drive enhanced and durable protein expression. The company has generated compelling preclinical data showing up to 15-fold enhanced and 70-fold more durable expression versus linear mRNA, and is actively pursuing partnerships and internal development across gene therapy, cell therapy, and vaccines. Its strategy involves advancing the circVec platform through its Swedish R&D subsidiary while out-licensing its clinical-stage oncology asset TG01 to external collaborators for further development.

Therapeutic Areas